Document is current
Any future updates will be listed below
-
Authors
Chen, Wenjie
Chen, Xinyu
Chen, Cheng
She, Shiqi
Li, Xia
Shan, Lina
Zhang, Xiaobing
Dan, Songsong
Wang, Yisha
Zhou, Yan-Wen
Cao, Qingyi
Wang, Wenxin
Hu, Jianwen
Wei, Yaxun
Xue, Yaqiang
Zhang, Yi
Zhang, Songying
Wang, Ying-Jie https://orcid.org/0000-0002-6888-9542
Kang, Bo
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (32170739)
- License Information
-
More Information
Article History
Received: 6 August 2024
Accepted: 11 February 2025
First Online: 23 February 2025
Declarations
:
: Human (h) ESC line H1 (SCSP-301) cells () and H9 (SCSP-302) cells () were acquired from the Cell Bank of the Chinese Academic of Sciences, Shanghai, China, under Material Transfer Agreements. The Cell Bank obtained prior ethical approval from WiCell Research Institute for the collection of hESC lines. The handling, storage and preparation of those cells was conducted following the protocols provided by the Cell Bank. All experiments using the obtained hESC lines in this study were approved by the Research Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University, and were performed according to institutional guidelines. Title of the approved project: Endogenous OCT4 promoter-driven reporter system to study self-renewal of pluripotent and cancer stem cells. Name of the institutional approval committee or unit: Research Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University. Approval number: 2019–377. Date of approval: February 8, 2019.
: Not applicable.
: The authors declare that they have no conflict of interest.
